胃肠治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024 年全球胃肠道治疗市场价值为 425 亿美元，预计到 2034 年将以 5.9% 的复合年增长率增长至 748 亿美元。这一市场扩张很大程度上是由于发炎性肠道疾病 (IBD)、胃食道逆流症 (GERD) 和消化性溃疡等胃肠道 (GI) 疾病盛行率的上升所致。随着成年人口的不断增长，慢性胃肠道疾病的发病率也在上升，从而形成了更大的患者群体，并增加了对专科治疗的需求。未经治疗的胃肠道疾病可导致严重的併发症，包括大肠直肠癌和中毒性巨结肠，尤其是在溃疡性结肠炎等情况下。这些趋势凸显了对有效的长期疗法的需求，从而推动了对生物製剂和标靶疗法等先进治疗方案的需求。

生物製剂和生物相似药的开发在加速市场成长方面发挥了关键作用。这些疗法已被证明能够有效治疗胃肠道疾病，透过标靶治疗控制发炎并帮助维持长期缓解。研发投入的增加以及监管部门的持续审批推动了该领域的创新。此外，公众对胃肠道健康的认识不断提高、诊断工具的进步以及新兴经济体医疗保健覆盖面的扩大，使得这些疗法更容易被更广泛的人群所接受，从而进一步支持了市场成长。

2024年，生物製剂和生物相似药市场规模达196亿美元，预计2034年将达到361亿美元，复合年增长率为6.4%。这些疗法已成为治疗克隆氏症和溃疡性结肠炎等疾病的首选方案。生物製剂提供了一种针对性的发炎控制方法，而生物相似药则透过降低治疗成本，增加了这些疗法的可及性，使全球患者能够负担得起。近期，关键药物的生物相似药获批，进一步促进了先进疗法的可及性。

2024年，成人市场规模达263亿美元，预计将维持主导地位，2034年复合年增长率达5.6%。成年人口尤其容易罹患慢性胃肠道疾病，例如克隆氏症、溃疡性结肠炎、胃食道逆流（GERD）和其他相关疾病。盛行率的上升很大程度上是由现代生活方式因素造成的，例如不良的饮食选择、高压力水平和久坐习惯，所有这些都会导致需要长期医疗照护的胃肠道问题增加。为了满足日益增长的需求，製药公司正在推进标靶药物製剂和给药方法的开发，包括注射和缓释片，旨在提高治疗效果并增强患者依从性。

北美胃肠道治疗市场在2024年达到178亿美元，预计2034年将达到307亿美元，复合年增长率为5.6%。北美强大的市场地位得益于其先进的医疗基础设施、对消化系统健康的高度重视以及现代治疗方案的广泛可及性。领先製药公司的涌现以及持续的创新和研发投入，持续推动市场的发展。生物技术公司与研究机构之间的合作伙伴关係进一步加速了新型疗法的开发和应用，确保北美在全球胃肠道治疗市场中继续保持关键地位。

参与全球胃肠道治疗市场的知名公司包括武田製药、葛兰素史克、礼来公司、强生、西普拉、阿斯特捷利康、百健、辉瑞、拜耳、赛诺菲、太阳製药、艾伯维、Phathom Pharmaceuticals 和雷迪博士实验室。胃肠道治疗市场的领先公司正致力于透过生物製剂和生物相似药的创新来扩大其产品组合。许多公司正在投资尖端研究，以开发更有效的治疗方法来解决胃肠道疾病的根本原因。与研究机构和生技公司的合作也是加速药物开发和商业化的常见策略。此外，公司正优先考虑地理扩张，特别是在新兴市场，透过使治疗更容易获得和负担得起。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
  • 供应商格局
  • 每个阶段的增值
  • 影响价值链的因素
• 产业衝击力
  • 成长动力
    • 胃肠道疾病盛行率上升
    • 药物研发不断取得进展
    • 提高胃肠道健康意识和预防保健措施
    • 增加研发投入和活动
  • 产业陷阱与挑战
    • 药物的不良反应
  • 市场机会
    • 人们对肠道微生物组研究的兴趣日益浓厚
    • 数位健康平台正在改善胃肠道治疗的可近性
• 成长潜力分析
• 管道分析
• 监管格局
• 未来市场趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 关键进展
  • 併购
  • 伙伴关係和合作
  • 扩张计划

第五章：市场估计与预测：按药物类型，2021 - 2034 年

• 主要趋势
• 止泻药
• 泻药
• 生物製剂/生物相似药
• 止吐药
• 抗溃疡药
• 抗生素
• 抗酸药
• 质子帮浦抑制剂（PPI）
• 其他药物类型

第六章：市场估计与预测：依疾病类型，2021 - 2034 年

• 主要趋势
• 发炎性肠道疾病（IBD）
  • 克罗恩病
  • 溃疡性结肠炎
• 胃食道逆流症（GERD）
  • 第一阶段
  • 第 2 阶段
  • 第 3 阶段
  • 第四阶段
• 消化性溃疡病
• 肠躁症（IBS）
  • 肠躁症（IBS）
  • 肠躁症（IBS）
  • 肠躁症
• 其他疾病类型

第七章：市场估计与预测：按药物类型，2021 - 2034 年

• 主要趋势
• 品牌
• 泛型

第八章：市场估计与预测：按年龄组，2021 - 2034 年

• 主要趋势
• 儿科
• 成人
• 老年

第九章：市场估计与预测：按管理路线，2021 - 2034 年

• 主要趋势
• 口服
• 肠外

第 10 章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第 11 章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十二章：公司简介

• AbbVie
• AstraZeneca
• Bayer
• Biogen
• Cipla
• Dr. Reddy's Laboratories
• Eli Lilly and Company
• GlaxoSmithKline
• Glenmark Pharmaceuticals
• Johnson & Johnson
• Novo Nordisk
• Pfizer
• Phathom Pharmaceuticals
• Sanofi
• Sun Pharma
• Takeda Pharmaceutical

The Global Gastrointestinal Therapeutics Market was valued at USD 42.5 billion in 2024 and is estimated to grow at a CAGR of 5.9% to reach USD 74.8 billion by 2034. This market expansion is largely driven by the rising prevalence of gastrointestinal (GI) disorders, such as inflammatory bowel disease (IBD), gastroesophageal reflux disease (GERD), and peptic ulcer disease. As the adult population continues to expand, the incidence of chronic GI conditions is also on the rise, creating a larger patient base and increasing demand for specialized treatments. Untreated GI conditions can lead to severe complications, including colorectal cancer and toxic megacolon, particularly in cases like ulcerative colitis. These trends highlight the need for effective, long-term therapies, fueling the demand for advanced treatment options such as biologics and targeted therapies.

The development of biologics and biosimilars has played a critical role in accelerating market growth. These therapies have proven to be highly effective in managing GI disorders by providing targeted treatments that control inflammation and help maintain long-term remission. Increased investment in research and development (R&D), along with a steady stream of regulatory approvals, has driven innovation in the field. Additionally, improved public awareness of GI health, advancements in diagnostic tools, and the expansion of healthcare access in emerging economies have made these treatments more available to a broader population, further supporting market growth.

The biologics and biosimilars segment was valued at USD 19.6 billion in 2024 and is expected to reach USD 36.1 billion by 2034, growing at a CAGR of 6.4%. These treatments have become the preferred option for managing conditions like Crohn's disease and ulcerative colitis. Biologics offer a targeted approach to inflammation control, while biosimilars have increased access to these therapies by lowering the cost of treatment, making them more affordable for patients worldwide. The recent approval of biosimilars for key drugs has further contributed to the growing accessibility of advanced treatments.

In 2024, the adult segment generated USD 26.3 billion and is projected to maintain its dominant position, growing at a CAGR of 5.6% through 2034. The adult population is especially vulnerable to chronic gastrointestinal (GI) conditions like Crohn's disease, ulcerative colitis, GERD, and other related disorders. This increased prevalence is largely driven by modern lifestyle factors, such as poor dietary choices, high stress levels, and sedentary habits, all of which contribute to a rise in GI issues that require long-term medical care. To meet the growing demand, pharmaceutical companies are advancing the development of targeted drug formulations and delivery methods, including injectables and sustained-release tablets, aimed at improving treatment efficacy and enhancing patient compliance.

North America Gastrointestinal Therapeutics Market generated USD 17.8 billion in 2024 and is expected to generate USD 30.7 billion by 2034, growing at a CAGR of 5.6%. North America's strong market position is attributed to its advanced healthcare infrastructure, high awareness of digestive health, and widespread access to modern treatment options. The presence of leading pharmaceutical companies, along with ongoing innovation and research efforts, continues to drive the market. Collaborative partnerships between biotech firms and research institutions further accelerate the development and availability of novel therapies, ensuring that North America remains a key player in the global GI therapeutics market.

Notable companies involved in the Global Gastrointestinal Therapeutics Market include Takeda Pharmaceutical, GlaxoSmithKline, Eli Lilly and Company, Johnson & Johnson, Cipla, AstraZeneca, Biogen, Pfizer, Bayer, Sanofi, Sun Pharma, AbbVie, Phathom Pharmaceuticals, and Dr. Reddy's Laboratories. Leading companies in the gastrointestinal therapeutics market are focusing on expanding their product portfolios through innovation in biologics and biosimilars. Many are investing in cutting-edge research to develop more effective treatments that address the underlying causes of GI disorders. Partnerships with research institutions and biotech firms are also a common strategy to accelerate drug development and commercialization. Additionally, companies are prioritizing geographical expansion, particularly in emerging markets, by making treatments more accessible and affordable.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Drug type
  • 2.2.3 Disease type
  • 2.2.4 Medication type
  • 2.2.5 Age group
  • 2.2.6 Route of administration
  • 2.2.7 Distribution channel
• 2.3 CXO perspectives: Strategic imperatives
  • 2.3.1 Key decision points for industry executives
  • 2.3.2 Critical success factors for market players
• 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Value addition at each stage
  • 3.1.3 Factor affecting the value chain
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of gastrointestinal diseases
    • 3.2.1.2 Growing advancements in drug development
    • 3.2.1.3 Increasing awareness and preventive care measures for gastrointestinal health
    • 3.2.1.4 Increased R&D investment and activities
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse effects of medication
  • 3.2.3 Market opportunities
    • 3.2.3.1 Growing interest in gut microbiome research
    • 3.2.3.2 Digital health platforms are improving access to GI treatments
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 Expansion plans

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Antidiarrheals
• 5.3 Laxatives
• 5.4 Biologics/ biosimilars
• 5.5 Antiemetics
• 5.6 Antiulcer agents
• 5.7 Antibiotics
• 5.8 Antacids
• 5.9 Proton pump inhibitors (PPIs)
• 5.10 Other drug types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Inflammatory bowel disease (IBD)
  • 6.2.1 Crohn's disease
  • 6.2.2 Ulcerative colitis
• 6.3 Gastroesophageal reflux disease (GERD)
  • 6.3.1 Stage 1
  • 6.3.2 Stage 2
  • 6.3.3 Stage 3
  • 6.3.4 Stage 4
• 6.4 Peptic ulcer disease
• 6.5 Irritable bowel syndrome (IBS)
  • 6.5.1 IBS-D
  • 6.5.2 IBS-C
  • 6.5.3 IBS-M
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Medication Type, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Branded
• 7.3 Generics

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Pediatric
• 8.3 Adult
• 8.4 Geriatric

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 Oral
• 9.3 Parenteral

Chapter 10 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 Hospital pharmacies
• 10.3 Retail pharmacies
• 10.4 Online pharmacies

Chapter 11 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 11.1 Key trends
• 11.2 North America
  • 11.2.1 U.S.
  • 11.2.2 Canada
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 France
  • 11.3.4 Spain
  • 11.3.5 Italy
  • 11.3.6 Netherlands
• 11.4 Asia Pacific
  • 11.4.1 China
  • 11.4.2 Japan
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 South Korea
• 11.5 Latin America
  • 11.5.1 Brazil
  • 11.5.2 Mexico
  • 11.5.3 Argentina
• 11.6 Middle East and Africa
  • 11.6.1 South Africa
  • 11.6.2 Saudi Arabia
  • 11.6.3 UAE

Chapter 12 Company Profiles

• 12.1 AbbVie
• 12.2 AstraZeneca
• 12.3 Bayer
• 12.4 Biogen
• 12.5 Cipla
• 12.6 Dr. Reddy’s Laboratories
• 12.7 Eli Lilly and Company
• 12.8 GlaxoSmithKline
• 12.9 Glenmark Pharmaceuticals
• 12.10 Johnson & Johnson
• 12.11 Novo Nordisk
• 12.12 Pfizer
• 12.13 Phathom Pharmaceuticals
• 12.14 Sanofi
• 12.15 Sun Pharma
• 12.16 Takeda Pharmaceutical